Sarah J Danson1, Christine Rowland2, Richard Rowe3, Sue Ellis4, Carol Crabtree4, Janet M Horsman4, Jonathan Wadsley5, Matthew Q Hatton5, Penella J Woll4, Christine Eiser3. 1. Academic Unit of Clinical Oncology, University of Sheffield, Whitham Road, Sheffield, S10 2SJ, UK. s.danson@shef.ac.uk. 2. Manchester Centre for Health Psychology, School of Psychological Sciences, University of Manchester, Manchester, UK. 3. Department of Psychology, University of Sheffield, Sheffield, UK. 4. Academic Unit of Clinical Oncology, University of Sheffield, Whitham Road, Sheffield, S10 2SJ, UK. 5. Department of Oncology, Weston Park Hospital, Sheffield, UK.
Abstract
PURPOSE: Smoking is a major cause of lung cancer, and continued smoking may compromise treatment efficacy and quality of life (health-related quality of life (HRQoL)) in patients with advanced lung cancer. Our aims were to determine (i) preference for treatments which promote quality over length of life depending on smoking status, (ii) the relationship between HRQoL and smoking status at diagnosis (T1), after controlling for demographic and clinical variables, and (iii) changes in HRQoL 6 months after diagnosis (T2) depending on smoking status. METHODS: Two hundred ninety-six patients with advanced lung cancer were given questionnaires to assess HRQoL (EORTC QLQ-C30), time-trade-off for life quality versus quantity (QQQ) and smoking history (current, former or never smoker) at diagnosis (T1) and 6 months later (T2). Medical data were extracted from case records. RESULTS: Questionnaires were returned by 202 (68.2 %) patients at T1 and 114 (53.3 %) at T2. Patients favoured treatments that would enhance quality of life over increased longevity. Those who continued smoking after diagnosis reported worse HRQoL than former smokers or those who never smoked. Smoking status was a significant independent predictor of coughing in T1 (worse in smokers) and cognitive functioning in T2 (better in never smokers). CONCLUSIONS: Smoking by patients with advanced lung cancer is associated with worse symptoms on diagnosis and poorer HRQoL for those who continue smoking. The results have implications to help staff explain the consequences of smoking to patients.
PURPOSE: Smoking is a major cause of lung cancer, and continued smoking may compromise treatment efficacy and quality of life (health-related quality of life (HRQoL)) in patients with advanced lung cancer. Our aims were to determine (i) preference for treatments which promote quality over length of life depending on smoking status, (ii) the relationship between HRQoL and smoking status at diagnosis (T1), after controlling for demographic and clinical variables, and (iii) changes in HRQoL 6 months after diagnosis (T2) depending on smoking status. METHODS: Two hundred ninety-six patients with advanced lung cancer were given questionnaires to assess HRQoL (EORTC QLQ-C30), time-trade-off for life quality versus quantity (QQQ) and smoking history (current, former or never smoker) at diagnosis (T1) and 6 months later (T2). Medical data were extracted from case records. RESULTS: Questionnaires were returned by 202 (68.2 %) patients at T1 and 114 (53.3 %) at T2. Patients favoured treatments that would enhance quality of life over increased longevity. Those who continued smoking after diagnosis reported worse HRQoL than former smokers or those who never smoked. Smoking status was a significant independent predictor of coughing in T1 (worse in smokers) and cognitive functioning in T2 (better in never smokers). CONCLUSIONS: Smoking by patients with advanced lung cancer is associated with worse symptoms on diagnosis and poorer HRQoL for those who continue smoking. The results have implications to help staff explain the consequences of smoking to patients.
Entities:
Keywords:
Lung cancer; Quality of life; Smoking; Smoking cessation
Authors: Mark S Walker; Damon J Vidrine; Ellen R Gritz; Randy J Larsen; Yan Yan; Ramaswamy Govindan; Edwin B Fisher Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-11-28 Impact factor: 4.254
Authors: Daniel Keizman; Maya Gottfried; Maya Ish-Shalom; Natalie Maimon; Avivit Peer; Avivit Neumann; Hans Hammers; Mario A Eisenberger; Victoria Sinibaldi; Roberto Pili; Henry Hayat; Svetlana Kovel; Avishay Sella; Ben Boursi; Rony Weitzen; Wilmosh Mermershtain; Keren Rouvinov; Raanan Berger; Michael A Carducci Journal: Oncologist Date: 2013-12-05
Authors: Úrsula Martínez; Karen O Brandon; Steven K Sutton; Thomas H Brandon; Vani N Simmons Journal: Psychooncology Date: 2019-07-02 Impact factor: 3.894
Authors: Jamie S Ostroff; Elyse R Park; Brett M Goshe; Autumn W Rasmussen; Lynne I Wagner; JoRean D Sicks; Ilana F Gareen; Ruth C Carlos; Benjamin A Herman; Angela Wangari Walter; Susan Regan; Douglas E Levy; Irene Mahon; Alona Muzikansky; Jordan M Neil; Michelle Lui; Deepika Dilip; Laura Malloy; Irina Gonzalez; Lucy Finkelstein-Fox; Caitlin McCann; Elissa Perez Journal: BMC Public Health Date: 2022-07-15 Impact factor: 4.135
Authors: Elyse R Park; Sarah E Skurla; Grelda Yazmin Juarez Caballero; Emily R Friedman; Colin Ponzani; Robert Wallace; Jennifer Malin; Nancy L Keating Journal: Support Care Cancer Date: 2022-05-12 Impact factor: 3.359
Authors: Elyse R Park; Jamie S Ostroff; Giselle K Perez; Kelly A Hyland; Nancy A Rigotti; Sarah Borderud; Susan Regan; Alona Muzikansky; Emily R Friedman; Douglas E Levy; Susan Holland; Justin Eusebio; Lisa Peterson; Julia Rabin; Jacob Miller-Sobel; Irina Gonzalez; Laura Malloy; Maureen O'Brien; Suhana de León-Sanchez; C Will Whitlock Journal: Contemp Clin Trials Date: 2016-07-19 Impact factor: 2.226
Authors: Godfred O Antwi; David K Lohrmann; Wasantha Jayawardene; Angela Chow; Cecilia S Obeng; Aaron M Sayegh Journal: J Cancer Educ Date: 2022-06 Impact factor: 1.771
Authors: Paul M Cinciripini; Maher Karam-Hage; George Kypriotakis; Jason D Robinson; Vance Rabius; Diane Beneventi; Jennifer A Minnix; Janice A Blalock Journal: JAMA Netw Open Date: 2019-09-04